Wengen Wu

1.3k total citations
23 papers, 821 citations indexed

About

Wengen Wu is a scholar working on Oncology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Wengen Wu has authored 23 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Cellular and Molecular Neuroscience. Recurrent topics in Wengen Wu's work include Peptidase Inhibition and Analysis (16 papers), Neuropeptides and Animal Physiology (8 papers) and Protease and Inhibitor Mechanisms (5 papers). Wengen Wu is often cited by papers focused on Peptidase Inhibition and Analysis (16 papers), Neuropeptides and Animal Physiology (8 papers) and Protease and Inhibitor Mechanisms (5 papers). Wengen Wu collaborates with scholars based in United States, China and Australia. Wengen Wu's co-authors include Jack H. Lai, William W. Bachovchin, David G. Sanford, Sarah E. Poplawski, James L. Sudmeier, Daniel A. Bachovchin, Todd R. Golub, Zhiping Jin, Matthew T. DiMare and Yuhong Zhou and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and PLoS ONE.

In The Last Decade

Wengen Wu

23 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wengen Wu United States 14 480 353 172 134 127 23 821
Joseph Brueggen Switzerland 8 617 1.3× 216 0.6× 105 0.6× 59 0.4× 103 0.8× 11 895
Rudi Baron United States 19 753 1.6× 224 0.6× 178 1.0× 105 0.8× 30 0.2× 27 1.1k
Thomas B. Sundberg United States 14 765 1.6× 297 0.8× 110 0.6× 80 0.6× 20 0.2× 17 1.0k
Amy E. Adams United States 10 479 1.0× 261 0.7× 22 0.1× 53 0.4× 91 0.7× 14 724
Michelle L. Kraus United States 7 466 1.0× 447 1.3× 96 0.6× 129 1.0× 284 2.2× 9 1.1k
Shama Kajiji United States 14 372 0.8× 497 1.4× 41 0.2× 75 0.6× 28 0.2× 23 1.1k
Edwige Nicodème France 8 1.2k 2.4× 207 0.6× 54 0.3× 60 0.4× 20 0.2× 11 1.5k
Bridget A. Quinn United States 16 454 0.9× 408 1.2× 32 0.2× 110 0.8× 49 0.4× 24 965
Kylie A. Hotchkiss United States 12 622 1.3× 224 0.6× 49 0.3× 169 1.3× 12 0.1× 13 1.0k
Françoise Perron‐Sierra France 14 517 1.1× 135 0.4× 156 0.9× 108 0.8× 14 0.1× 22 925

Countries citing papers authored by Wengen Wu

Since Specialization
Citations

This map shows the geographic impact of Wengen Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wengen Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wengen Wu more than expected).

Fields of papers citing papers by Wengen Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wengen Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wengen Wu. The network helps show where Wengen Wu may publish in the future.

Co-authorship network of co-authors of Wengen Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Wengen Wu. A scholar is included among the top collaborators of Wengen Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wengen Wu. Wengen Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Poplawski, Sarah E., Robin Hallett, Shuang Pan, et al.. (2023). Preclinical Development of PNT6555, a Boronic Acid–Based, Fibroblast Activation Protein-α (FAP)–Targeted Radiotheranostic for Imaging and Treatment of FAP-Positive Tumors. Journal of Nuclear Medicine. 65(1). 100–108. 20 indexed citations
2.
Panaro, Brandon L., Jacqueline L. Beaudry, Elodie M. Varin, et al.. (2018). Fibroblast activation protein is dispensable for control of glucose homeostasis and body weight in mice. Molecular Metabolism. 19. 65–74. 19 indexed citations
3.
DiMare, Matthew T., et al.. (2016). Human FGF-21 Is a Substrate of Fibroblast Activation Protein. PLoS ONE. 11(3). e0151269–e0151269. 54 indexed citations
4.
Okondo, Marian C., Darren C. Johnson, Ramya Sridharan, et al.. (2016). DPP8 and DPP9 inhibition induces pro-caspase-1-dependent monocyte and macrophage pyroptosis. Nature Chemical Biology. 13(1). 46–53. 226 indexed citations
5.
Akopian, Tatos, Olga Kandror, Christopher Tsu, et al.. (2015). Cleavage Specificity of Mycobacterium tuberculosis ClpP1P2 Protease and Identification of Novel Peptide Substrates and Boronate Inhibitors with Anti-bacterial Activity. Journal of Biological Chemistry. 290(17). 11008–11020. 48 indexed citations
6.
Bachovchin, Daniel A., Luke W. Koblan, Wengen Wu, et al.. (2014). A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity. Nature Chemical Biology. 10(8). 656–663. 60 indexed citations
7.
8.
Wilkins, Marc R., Angelina J. Lay, Dominik C. Kaczorowski, et al.. (2014). Sphingosine Kinase 1 Isoform-Specific Interactions in Breast Cancer. Molecular Endocrinology. 28(11). 1899–1915. 20 indexed citations
9.
Duncan, Brynn B., Steven L. Highfill, Haiying Qin, et al.. (2013). A Pan-Inhibitor of DASH Family Enzymes Induces Immune-mediated Regression of Murine Sarcoma and Is a Potent Adjuvant to Dendritic Cell Vaccination and Adoptive T-cell Therapy. Journal of Immunotherapy. 36(8). 400–411. 12 indexed citations
10.
Poplawski, Sarah E., Jack H. Lai, Youhua Li, et al.. (2013). Identification of Selective and Potent Inhibitors of Fibroblast Activation Protein and Prolyl Oligopeptidase. Journal of Medicinal Chemistry. 56(9). 3467–3477. 88 indexed citations
11.
Wu, Wengen, Youhua Li, Peng Zhao, et al.. (2013). A General Method for Making Peptide Therapeutics Resistant to Serine Protease Degradation: Application to Dipeptidyl Peptidase IV Substrates. Journal of Medicinal Chemistry. 56(21). 8339–8351. 17 indexed citations
12.
Wu, Wengen, Yuxin Liu, Peng Zhao, et al.. (2012). 4-Substituted boro-proline dipeptides: Synthesis, characterization, and dipeptidyl peptidase IV, 8, and 9 activities. Bioorganic & Medicinal Chemistry Letters. 22(17). 5536–5540. 10 indexed citations
13.
Lai, Jack H., Wengen Wu, Yuxin Liu, et al.. (2011). Chemical and Biological Evaluation of Dipeptidyl Boronic Acid Proteasome Inhibitors for Use in Prodrugs and Pro-Soft Drugs Targeting Solid Tumors. Journal of Medicinal Chemistry. 54(13). 4365–4377. 70 indexed citations
14.
Connolly, Beth A., David G. Sanford, Diane E. Peters, et al.. (2008). Dipeptide Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: Determinants of Potency and in Vivo Efficacy and Safety. Journal of Medicinal Chemistry. 51(19). 6005–6013. 60 indexed citations
15.
Lai, Jack H., Wengen Wu, Yuhong Zhou, et al.. (2007). Synthesis and Characterization of Constrained Peptidomimetic Dipeptidyl Peptidase IV Inhibitors:  Amino-Lactam boroAlanines. Journal of Medicinal Chemistry. 50(10). 2391–2398. 13 indexed citations
16.
Lai, Jack H., Yuhong Zhou, James L. Sudmeier, et al.. (2005). Microscopic Acid-Base Equilibra of Alanyl-boroAlanine. Kluwer Academic Publishers eBooks. 524. 333–338. 2 indexed citations
17.
Lai, Jack H., Yuxin Liu, Wengen Wu, et al.. (2005). Synthesis and Structural Investigation of Internally Coordinated α-Amidoboronic Acids. The Journal of Organic Chemistry. 71(2). 512–519. 13 indexed citations
18.
Ma, Dawei, et al.. (2003). Tetrahydroisoquinoline based sulfonamide hydroxamates as potent matrix metalloproteinase inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(1). 47–50. 27 indexed citations
19.
Ma, Dawei, Wengen Wu, & Ping Deng. (2001). Facile synthesis of (+)-α-allokainic acid via Pd-catalyzed hydrogenolysis of allyl acetate derived from trans-4-hydroxy-l-proline. Tetrahedron Letters. 42(39). 6929–6931. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joseph Brueggen Breakdown of academic impact, for papers by Rudi Baron Breakdown of academic impact, for papers by Thomas B. Sundberg Breakdown of academic impact, for papers by Amy E. Adams Breakdown of academic impact, for papers by Michelle L. Kraus Breakdown of academic impact, for papers by Shama Kajiji Breakdown of academic impact, for papers by Edwige Nicodème Breakdown of academic impact, for papers by Bridget A. Quinn Breakdown of academic impact, for papers by Kylie A. Hotchkiss Breakdown of academic impact, for papers by Françoise Perron‐Sierra
Rankless by CCL
2026